Top Mutual Funds
Result PDFQ1FY25 Quarterly Result Announced for Indegene Ltd.
Pharmaceuticals company Indegene announced Q1FY25 results:
- Achieved revenue of Rs 6,765 million in Q1FY25 with growth of 11.4% vs Q1FY24
- Robust EBITDA growth of 14.5% in Q1FY25 vs Q1FY24
- Became a zero-debt company
Manish Gupta, Chairman and CEO, Indegene, said: “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased activity and volume levels tracking the larger pipeline of impending new product launches"
“Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is heathier and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.”
Suhas Prabhu, CFO, Indegene, said: “Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward”
“Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.”
